Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Denali Therapeutics's Tividenofusp alfa?
Tividenofusp alfa is a fusion protein commercialized by Denali Therapeutics, with a leading Phase III program in Mucopolysaccharidosis II (MPS...
Data Insights
Risk adjusted net present value: What is the current valuation of Denali Therapeutics's Tividenofusp alfa?
Tividenofusp alfa is a fusion protein commercialized by Denali Therapeutics, with a leading Phase III program in Mucopolysaccharidosis II (MPS...